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1. Introduction 
Grapevine is one of the ancient crops linked with human history during the evolutionary 
development of man. The fruits and wine have taken part in daily life and ancient 
ceremonies of our predecessors and currently grapevine is one of the most widely cultivated 
fruit crop in the world. It is consumed fresh, dry or as beverage but the most popular 
consumption form in the world is wine. Recent decades researchers found another reason to 
praise grape products: its beneficial effect on health. In the late Eighties grape and wine 
have been in the spotlight because of the finding of so called ‘French Paradox’ that linked 
moderate red wine consumption to a lower incidence of cardiovascular disease. As an 
addition, epidemiological studies demonstrated the beneficial effect of moderate wine 
intake on the neurodegenerative process (Marambaud et al., 2005). These findings gave 
boost to numerous studies of grape and wine effects on health, revealing evidences about 
the protective effect of grape compounds against cancer and age-related disorders, such as 
certain neurological diseases and metabolic disorders. Moreover, scientists proved that 
some compounds of grape are implicated in important biological functions in the body such 
as antioxidant defense system, immunological regulation and anti-inflammatory processes. 
The main question is what makes grape so useful and healthy?  
The answer is found in the fruit and wine constituents, i.e. grape secondary metabolites. The 
secondary metabolites are exclusively produced by plants and represent more than 30 000 
different substances that give individual properties of plant species and define them as 
healthy, healing or even poisonous. Grape is rich in secondary metabolites which makes this 
fruit crop so popular among the scientific society. Different research groups have 
undertaken the study of grape metabolomics and revealed the rich profile of grape and 
wine, including polyphenols such as resveratrol, caffeic acid, catechin, quercetin etc., all of 
which present highly bioactive substances. In recent years the analyses of grape composition 
and its effect on human health led to the conclusion that resveratrol is one of the key grape 
substances responsible for the preventive and therapeutic abilities of wine. Recent study of 
Iriti et al. (2006) discovered another key substance in grape - melatonin, which is considered 
for one of the most powerful antioxidants involved in various physiological functions in 
human body (Srinivasan et al., 2006). It is noteworthy that the health promoting effects of 
grape and wine are due to the secondary metabolites presented in them.  
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2. Resveratrol 
Resveratrol is one of the polyphenol substances which are considered to have antioxidant 
activities and to extend life (Lagouge et al., 2006). Resveratrol is a stilbene which is produced 
naturally by more than 70 plant species as a defensive reaction against pathogens or under 
stress conditions (UV radiation). As far as resveratrol is a phytoalexin it is produced in 
plants during the process of a long-term resistance to a certain pathogens or abiotic stress 
and it is reported that in grapes resveratrol provides a resistance to fungal diseases (LeBlanc, 
2006). Resveratrol is soluble in fats and exists in two isomeric forms: cis and trans. Both 
forms could be bound to a glucose molecule so that resveratrol also occurs naturally as 
glucoside in grapes which is known as piceid.  
Resveratrol is naturally occurring in grapevines where it is almost exclusively synthesized 
in berry skins, but in muscadine grapes it is found also in seeds (LeBlanc, 2006). The content 
of this substance in red grapes is higher than in white ones. Total resveratrol content in 100 g 
red grapes varies between 0.15 mg and 0.78 mg. It is estimated that fresh grape skins contain 
between 50 and 100 μg resveratrol per gram wet weight (Baliga et al., 2005). The levels of 
resveratrol in grape are influenced by grape cultivar, its geographic origin and exposure to a 
fungal disease or other stress conditions. It is found that during the process of winemaking 
this substance could increase its content depending on fermentation time during which the 
wine spends in contact with the grape skins. Therefore, the content of resveratrol in white 
wines is considerably lower since this wine is made after removing the grape skins. In 
contrary red wine is fermented with the grape skins allowing the wine to absorb more 
quantity of resveratrol. Some reports suggest that during the winemaking process 
resveratrol glucosides (piceids) convert to resveratrol and thus the higher concentration of 
the substance in wine in comparison of that found in fresh grape juice is explained (LeBlanc, 
2006). 
Recently, scientists are interested in biological activity of phytoalexins and their effect on 
human health. According to data concerning incidences of coronary heart disease collected 
from World Health Organization (WHO) in the period of 80s-90s last century, it is reported 
that French people suffer less from this disease despite having a diet relatively rich in 
saturated fats and this fact is known as a French paradox (LeBlanc, 2006). Different research 
groups were investigating the reason for French paradox and why French people have less 
incidences of coronary heart disease in comparison with Americans although the fact that 
French consume daily in average more saturated fats (15,6% of total energy intake) than 
American people (11,3% of total energy intake) (Elmadfa & Kornsteiner, 2009). It has been 
suggested that the high consumption of red wine in France is a primary factor for the French 
paradox. The data suggest that wine consumption reduces coronary heart diseases much 
more than other alcohol beverages and therefore the presence of other wine components 
different from alcohol provide higher prevention of heart diseases. An increased interest in 
wine bioactive compounds gave a boost in research of resveratrol and its effect on human 
health.  
2.1 Resveratrol and its cardioprotective effect 
The occurrence of the French paradox boosted the researchers to analyze the effect of 
resveratrol on people with a known predisposition to cardiovascular heart disease. A recent 
study of Sacanella et al. (2007) reported that 2 glasses of 100 ml red wine per day for 4 weeks 
is resulting in a greater reduction of inflammatory biomarkers, cellular adhesion molecules 
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and monocyte adhesion to endothelium, which is not found for the white wine. Resveratrol 
is a key constituent of red wine which has variety of activities associated with its 
cardioprotective effect. This assertion is well-founded with the results from Hung’s research 
showing that synthesized and purified trans-resveratrol is effective to prevent reperfusion-
induced arrhythmias and mortality in rats (Hung et al., 2000). It is considered that the 
protective mechanism of resveratrol is due to its activity as intracellular antioxidant, anti- 
inflammatory agent, and due to its ability to induce angiogenesis and expression of nitric 
oxide synthase (Bhat et al., 2001) as well to block low-density lipoprotein (LDL) 
peroxidation and increase the levels of high-density lipoprotein (HDL) (Petrovski et al., 
2011). In the study conducted by Klinge et al. (2008) are analyzed the signaling pathways 
and molecular mechanisms by which resveratrol in concentrations compatible with oral 
consumption (nanomolar concentrations) is activating the protection against coronary heart 
diseases and is improving the function of endothelium of blood vessels.  It is found that 
nanomolar concentration of this compound is enough to stimulate rapidly nitric oxide 
production in endothelial cells by increasing the interaction between estrogen receptor α-Src 
and calveolin-1, which is one of the components of signaling pathway of resveratrol’s 
protective action. As far as inflammation plays a key role in atherosclerosis, resveratrol can 
attenuate the condition through its anti-inflammatory effect, which involves inhibition of the 
synthesis of pro-inflammatory compounds such as prostaglandin E2 and interleukin-6 
(Petrovski et al., 2011). Another cardioprotective mechanism of resveratrol is its ability to 
inhibit platelet aggregation, thus preventing formation of thrombi (Petrovski et al., 2011).   
Another important side of resveratrol’s heart protective effect is its participation in so called 
‘preconditioning’ which is known to be one of the most powerful technique for promoting a 
cardioprotection (Das et al., 1993; Sato et al., 2000). The preconditioning includes several 
short cycles of reversible ischemia, each followed by another short duration of reperfusion. 
The process of preconditioning-mediated cardioprotection makes the heart resistant to 
subsequent lethal ischemic injury (Das & Maulik, 2006). Preconditioning induces the 
expression of some heat shock proteins and endogenous antioxidant enzymes such as 
superoxide dismutase and also enhances the signal transduction by activating the survival 
signals and inhibiting the death ones. Resent study of Das & Maulik (2006) reported that 
resveratrol may act as a phytopharmacological preconditioning agent by activation of 
signaling pathways of preconditioning. These pathways include activation of adenosine A1 
and A3 receptors, multiple kinases, KATP mitochondrial ATP-sensitive potassium channel 
and nitric oxide production - all of them are important factors with crucial role in 
preconditioning-mediated cardioprotection (Das & Maulik, 2006; Petrovski et al., 2011). 
Resveratrol provides cardioprotection by improving postischemic recovery and reducing 
the size of myocardial infarct and cardiomyocyte apoptosis (Das & Maulik, 2006). However, 
the mechanisms of enhancing the heart endogenous defense are not completely clear and 
more studies are necessary for better understanding of these signaling pathways. 
2.2 Resveratrol and its therapeutic potential in neurological disorders 
In addition to the cardioprotective effect of resveratrol, recent data suggest that this 
phytoalexine has protective and therapeutic potential against certain neurological disorders. 
Neurodegenerative diseases are one of the significant challenges of medicine and involve 
malfunction or progressive loss of structure of neurons and even cell death. Although the 
profound research in this area, so far the mechanisms of diseases pathologies are poorly 
understood. Many of these diseases are heritable and caused by genetic mutations. Other 
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causes of such disorders include toxins, chemicals and certain medical conditions such as 
alcoholism or stroke. With the research progress it has been hypothesized that the oxidative 
stress and damage caused by reactive oxygen species (ROS) play a major role in 
neurodegeneration (Pallàs et al., 2009). The oxidative stress is induced by imbalance 
between production and detoxification of ROS leading to damage of all cell components, 
including DNA, proteins, lipids and even neuronal messengers. This could lead to 
irreversible damage of neuron structure and function, thus contributing to the pathogenesis 
of neurodegeneration. Other toxic reactions that cause neurodegeneration involve 
inflammation and dysfunction of mitochondrial activity (Ramassamy, 2006). As far as 
resveratrol is reported to have a strong antioxidant and anti-inflammatory activity its 
beneficial properties could be used in the treatment and prevention of neurodegenerative 
diseases. Epidemiological studies have shown that the moderate red wine consumption is 
correlated with a significant reduction of Alzheimer’s disease and dementia (Marambaud et 
al., 2005; Orgogozo et al., 1997). Furthermore, in vivo studies with animals demonstrate the 
protective effect of resveratrol in models of neurotoxicity (Virgili & Contestabile, 2000). 
These results gave boost of studying the molecular targets of resveratrol as a potential 
phytoceutical in neurological diseases. The most common neurodegenerative disorders 
include Alzheimer’s, Parkinson’s and Huntington’s  diseases. 
2.2.1 Alzheimer’s disease (AD) 
AD is the most common form of dementia, which is associated with senile plaques caused 
by aggregation of ǃ-amyloid peptide (ǃAP). It has been shown that intra- and extra-cellular 
ǃAP is responsible for the initiation of synaptic malfunctions and occurrence of AD-
symptoms (Wirths et al., 2004). Yu and colleagues (2006) reported that ǃAPs can cause 
massive neuronal cell loss by inducing apoptosis. It is suggested that ǃAPs trigger the 
apoptosis by interaction with various neuronal receptors and free radical production that 
activate different cell-death-signalling pathways (Yuan & Yankner, 2000). Valerio et al. 
(2006) found that the activation of protein complex NF-kB in microglia plays a crucial role in 
ǃAP-induced neuronal cell death.  This signaling pathway can be modulated and 
significantly reduced by inhibition of the degradation of cytoplasmatic protein IkB that acts 
as an inhibitor of NF-kB. That very pathway is reported to be a target of resveratrol, where 
the grape compound inhibits the degradation of IkB thus showing neuroprotective and 
therapeutic effect (Pallàs et al., 2009).     
In a study Marambaud et al. (2005) investigated whether resveratrol is modulating the levels 
of βAPs in the neocortex and hippocampus of brains damaged from AD. The in vitro 
research reports that the βAP levels were significantly decreased in cells treated with 
resveratrol. Further in vitro experiments demonstrate that the polyphenol promotes 
intracellular degradation of βAPs without increasing the total protease activity (Marambaud 
et al., 2005).  
Another possible therapeutic mechanism of resveratrol is its similarity with the effects of 
calorie restriction. In the survey of Pallàs et al. (2009) are discussed studies, which 
demonstrated that short-term calorie restriction is associated with reduction of ǃAP-plaques 
in transgenic mouse models of AD. It is suggested that the dietary regime promotes 
processing of the amyloid precursor protein via pathway that does not result in ǃAPs. This 
is possible when the processing is made by α-secretase cleavage instead of ǃ- and Ǆ-
secretases. As far as resveratrol mimics the calorie restriction pathways, it can be 
hypothesized that it reduces the ǃAPs using the same pathway (Pallàs et al., 2009). 
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Moreover, ǃAPs induce apoptosis via production of reactive oxygen species, which can be 
scavenged by the strong anti-oxidation effect of resveratrol (Jang et al., 2007). These data 
prove that resveratrol stimulates the clearance of senile plaques and prevents from the 
neurotoxic effect of βAPs, thus having a neuroprotective effect. 
Inflammation, being associated with the development of AD, is another target of resveratrol. 
The anti-inflammatory properties of resveratrol have a beneficial effect on prevention and 
treatment of neurodegenerative process. 
2.2.2 Parkinson’s disease (PD) 
PD is another neurodegenerative disorder that is characterized by a selective death of 
dopamine-producing cells in the substantia nigra (Gao et al., 2002). As contributing factors 
to the disease, mitochondrial dysfunction, inflammation, oxidative stress and apoptosis 
appear to have a major role in the development and progression of PD.  Recent studies 
showed that resveratrol has neuroprotective function against the deleterious effect of  
6-hydroxydopamine (6-OHDA) in rat models of PD (Jin et al., 2008; Khan et al., 2010). The 
conducted trials revealed that resveratrol suppresses the expression of pro-inflammatory 
cytokines (TNF-α) and enzymes (COX-2), which play a key role in the inflammatory process 
that is related with the progression of neurodegenerative diseases. Jin et al. (2008) 
demonstrated that the overexpression of COX-2 and TNF-α mRNA is involved in the 
pathogenesis of PD and resveratrol can be used to reduce the levels of these proteins, 
resulting in improvement of pathological lesions in substantia nigra neurons in rat models 
of PD. These results confirm the beneficial effect of resveratrol in the treatment of PD. 
2.2.3 Huntington’s disease (HD) 
HD is a neurodegenerative genetic disorder caused by a mutation of the gene coding 
Huntingtin protein. The mutation results in synthesis of a different form of the protein that 
forms aggregates with neurotoxic effect leading to degeneration of specific brain areas. The 
mutant protein damages mitochondria in the affected neurons, causing dysfunction and 
death of the cells.  One of the experimental models of HD is the utilization of the neurotoxin 
3-nitropropionic acid on rodents. One of the major mechanisms of toxin action is the 
induction of mitochondrial dysfunction via oxidative stress. Several studies reported the 
protection activity of resveratrol against this neurotoxin and suggested that it was its 
antioxidant properties that are responsible for the prevention of the functional effect of the 
toxin (Binienda et al., 2010; Kumar et al., 2006). Furthermore, some authors reported that the 
beneficial effect of resveratrol is through activation of SIRT1 (Howitz et al., 2003; Lagouge et 
al., 2006). However, Pallos et al. (2008), working with Drosophila model of HD, 
demonstrated that resveratrol has a neuroprotective effect in a dose-dependent manner but 
through mechanisms that are independent of Sir2 activation (the human ortholog is SIRT1).  
Another research demonstrates that the phenolic constituents of red wine can inhibit the 
harmful effect of oxidative stress as a result of nitric oxide production (Bastianetto et al., 
2000), which is neurodegenerative event with damages relevant to those occurring during 
chronic inflammation, cerebral ischemia or excitotoxicity. The in vitro study showed that 
resveratrol is capable of protecting and rescuing rat’s hypothalamic cells against nitric oxide 
- induced toxicity (Bastianetto et al., 2000).  
Hence, the results from the above mentioned studies lead to the conclusion that the red 
wine polyphenol constitute, resveratrol, possesses a therapeutic potential and has a 
beneficial effect for the prevention of age-related neurodegenerative disorders. The data 
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about the antioxidant activities of resveratrol support the hypothesis of beneficial effects of 
moderate daily red wine consumption against the occurrence of neuropathological diseases 
of chronic or acute nature. Presented studies confirm the neuroprotective value of 
resveratrol and its ability to rescue neuron cells but yet the exact mechanisms and pathways 
of its action remain not fully revealed and further studies are needed. 
2.3 Resveratrol and its longevity and anti-ageing properties 
Ageing processes are determined by metabolic disorders which occur with the age 
increasing. Metabolic disorders are tightly linked to compromised mitochondrial functions 
(Petersen et al., 2003) as a result of reduced expression of genes controlling mitochondrial 
biogenesis  in humans and animals (Lagouge et al., 2006). Numerous studies revealed that 
the gene PGC-1α (peroxisome proliferator-activated receptor γ co-activator) has a crucial 
role in mitochondrial activity (Wu et al., 1999), skeletal muscle fiber-type switching 
(Puigserver & Spiegelman, 2003), controlling of adaptive thermogenesis (Puigserver et al., 
1998)  and together with SIRT1 gene promotes the adaptation to caloric restriction (Rodgers 
et al., 2005). SIRT1 gene encodes a member of sirtuin family of proteins and interacts with 
PGC-1α, taking part in regulation of longevity, apoptosis and DNA repair (Sinclair, 2005). 
Recent studies showed that resveratrol significantly increases the SIRT1 activity through 
allosteric interaction (Howitz et al., 2003). In the in vivo animal studies conducted by 
Lagouge et al. (2006) is demonstrated that resveratrol impacts on the regulation of energy 
homeostasis by inducing mitochondrial activity through increasing SIRT1 activity and thus 
modulating PGC-1α functions. In series of experiments is demonstrated that the intake of 
resveratrol 200 or 400 mg/kg/day has a beneficial effect on body weight by inducing a 
resistance to weight gain and enhances the adaptive thermogenesis by increasing the cold 
tolerance (Lagouge et al., 2006). Resveratrol treatment induces mitochondrial morphological 
changes in muscles and brown adipose tissue such as enlarging of mitochondrial structures 
and increasing presence of cristae and thus the polyphenol has a beneficial influence on the 
energy homeostasis and reduces the weight gaining in conditions of high fat diet.  
As far as resveratrol changes the morphological structure of mitochondria in muscles, this 
substance enhances the enzymatic activity of organelles and induces the muscle fiber-type 
switching resulting in increased resistance to muscle fatigue (Booth et al., 2002). All these 
data lead to the conclusion that resveratrol enhances mitochondrial activity resulting in 
suppression of ageing symptoms by increasing of fatty acid oxidation, amelioration of fat 
burning, maintaining of energy homeostasis and induction of muscle fatigue resistance.  
Besides its anti-ageing properties, there are evidences that resveratrol works as a longevity 
agent. In year 2003 the team of David Sinclair reported that resveratrol increases cell 
survival by stimulating SIRT1-dependent deacetylation of p53 tumor suppressor (Howitz et 
al., 2003). Nevertheless, some studies with yeast (Kaeberlein et al., 2004) and nematode 
Caenorhabditis elegans (Guarente & Picard, 2005) questioned the involvement of sirtuin in 
lifespan extension leaving this assertion quite controversial (Markus & Morris, 2008). These 
results suggest that the wide effects of resveratrol are not always a result of sirtuin 
activation. In the recent review of Markus & Morris (2008) is revealed that resveratrol is also 
involved in sirtuin-independent pathway which is central to the control of lifespan. In this 
pathway the target of resveratrol is PI3K (phosphoinositide 3-kinase) which implicates the 
polyphenol in insulin-like signaling pathway for activating of mitochondrial biogenesis 
(Frojdo et al., 2007).  
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The reports that resveratrol has positive effect on lifespan extension in mice prompt to more 
extensive research of in vivo resveratrol’s effects in mammals (Baur et al., 2006; Lagouge et 
al., 2006). The findings of the French (Lagouge et al., 2006) and American (Baur et al., 2006) 
research groups are promising for therapeutic properties of resveratrol in human metabolic 
disorders.  
3. Melatonin 
Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine, a naturally occurring 
compound found in animals, plants and microbes. In human body melatonin plays an 
important role for regulation of sleep-wake cycles, induction of immune system, sexual 
development and vascular tone (Iriti et al., 2006).  
For a long time it was thought that melatonin is a neurohormone exclusively synthesized in 
vertebrates, but in recent years it was found that this substance is presented in plants, 
bacteria, algae, fungi and invertebrates (Iriti & Faoro 2006).   Few years ago, Iriti et al. (2006) 
discovered melatonin in different grape cultivars, which gave a boost of series of studies 
concerning the presence and biosynthesis of this compound in grape and wine (Guerrero et 
al., 2008; Mercolini et al., 2008). Melatonin content in grape is reported to range from 5 to 96 
pg/g, while in wine the content was found to vary from 50-80 pg/ml (Spanish wines) to 
400-500 pg/ml (Italian wines) with higher content in red wines (Iriti et al., 2010). It was 
reported that the human serum concentration of melatonin significantly increases 1 hour 
after intake of 100 ml red wine (Guerrero et al., 2008), resulting in increased plasma 
antioxidant capacity. These results show that the effect of this neurohormone in humans 
could be modulated by moderate administration of wine.  Recent studies are directed to 
melatonin treatment of cancer, immune disorders, cardiovascular diseases, depression, 
circadian rhythm sleep disorders and sexual dysfunction. Therefore, the reported presence 
of melatonin in grape and wine gives an additional support to the hypothesis about the 
beneficial health effects of moderate wine consumption.  
3.1 Antioxidant properties of melatonin 
Melatonin is a pervasive substance whose powerful antioxidant property is particularly 
directed to a protection of nuclear and mitochondrial DNA by scavenging OH, O2- , H2O2, NO 
and inhibition of lipid peroxidation. Reiter et al. (2003) reported melatonin to be an efficient 
scavenger of free radicals in mitochondria, which are a major source of reactive species in 
the cell. Moreover, the authors reported that melatonin suppresses the apoptotic signals 
originating in mitochondria, thus diminishing disorders that are related to mitochondrial 
dysfunction – brain damages, age-related disease, etc. It was found that melatonin is 
effective against brain damages caused by release of free radicals containing oxygen atom 
(Tütüncüler et al., 2005) and also can reduce the brain damages caused by some types of 
Parkinson’s disease.  The antioxidant effect of melatonin provides a protection from 
neurodegeneration as well as from the mutagenic and carcinogenic actions of free radicals 
and thus, melatonin contributes enhancing of longevity (Oaknin-Bendahan et al., 1995). 
Other evidence concerning the strong antioxidative properties of melatonin is its positive 
effect for successful treatment for septic shock in newborns, which is discussed by Reiter et 
al. (2003). As far as the excessive free radical generation is considered to be one of the causes 
for sepsis the authors attributed the beneficial actions of melatonin to its antioxidant 
properties. Moreover, in this review the authors presented numerous evidences about the 
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positive effect of melatonin in treatment of a variety of conditions associated with elevated 
oxidative stress in newborns, children and adults (Reiter et al., 2003).   
So far, the obtained information from numerous studies, some of which are above 
mentioned, leads to the conclusion that melatonin acts on multiple ways for reduction of 
oxidative stress, i.e. direct scavenge of free radicals and reactive species, stimulation of 
antioxidative enzymes, stimulation of mitochondrial function, synergy with classic 
antioxidants, etc. The powerful direct and indirect antioxidant actions of melatonin, proved 
by in vitro and clinical tests, are promising for prevention and treatment of disease states 
that involve damage caused by free radicals.  
3.2 Melatonin effects on nervous system 
As far as melatonin in mammals plays a role of neurohormone, it is obviously that it is 
involved in various function associated with nervous system. It has a key role in regulation 
of circadian rhythm that coordinates sleep-wake cycle and takes part in modulation of mood 
and behavior. Since melatonin (exogenous and endogenous) possesses the ability to pass the 
blood-brain barrier it has a direct effect on brain. Moreover, it is reported that melatonin 
from edible plants binds to melatonin receptors in mammalian brain and exerts its biological 
activity (Iriti et al., 2010). Melatonin has a broad range of action, which is not limited only to 
the regulation of circadian rhythm. Findings from mice and rat trials have shown that 
melatonin receptors appear to play important role in mechanisms of learning and memory 
(Larson et al., 2006) as well as that melatonin facilitates short-term memory (Argyriou et al., 
1998). The study conducted by Baydas and co-workers (2002) suggested that the beneficial 
effect of melatonin on memory and learning processes could be due to its involvement in 
structural remodeling of synaptic connections during these processes. In another study is 
demonstrated the powerful antioxidant effect of melatonin in ethanol-treated rats where 
melatonin prevents lipid peroxidation in brain resulting from chronic ethanol exposure 
(Gönenç et al., 2005). 
The melatonin acts through three main mechanisms, namely receptor-mediated, protein-
mediated and non-receptor-mediated. The receptor-mediated activity of melatonin involves 
membrane (MT1 and MT2) and nuclear receptors (RORα and RZRǃ) and is responsible for 
the immune system and upregulation of antioxidant enzymes (Srinivasan et al., 2006). The 
non-receptor-madiated action of melatonin involves its antioxidant properties as a direct 
scavenger of reactive species.     
Interestingly, melatonin secretion decreases with ageing, which was suggested to be 
associated with the manifestation of age-related neurodegenerative diseases (Srinivasan et 
al., 2006). Moreover, it is reported a significant reduction of melatonin secretion in people 
with dementia in comparison with nondemented controls (Papolla et al., 1997), thus, 
suggesting exogenous melatonin to be extensively explored as a therapeutic and preventive 
agent in neurodegenerative diseases.  
3.2.1 Alzheimer’s disease (AD) 
It has been reported by many researchers that the melatonin levels are much lower in AD 
patients in comparison with the hormone levels detected in aged matched controls (Skene & 
Swaab, 2003). Another finding indicated one of the melatonin receptors (MT2) to mediate the 
melatonin effects in human hippocampus – a mechanism that appear to be impaired in AD 
patients (Savaskan et al., 2005). The study of Savaskan et al. (2005) is the first 
immunohistochemical assay that identifies the exact cellular distribution of MT2 in human 
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hippocampus and proves the altered expression and cellular loss of this receptor in AD 
patients. All these data prove the importance of melatonin and its targets for the 
neurological processes and suggest its beneficial effect for treatment of AD. 
As far as deposition of cerebral ǃAPs is a primary hallmark of AD, the effect of melatonin 
against the neurotoxic properties of ǃAPs is examined. It was found that melatonin prevents 
death of cultured neuronal cells caused by exposure to ǃAPs (Pappolla et al., 1997). As an 
addition, the oxidative stress, along with the neurotoxicity of ǃAPs, is proposed to play a 
significant role in the pathogenesis of AD lesions. Pappolla et al. (1992) first presented 
evidences that proof the role of oxidative damage in the development and progression of 
AD. These finding was confirmed by recent trial with transgenic mouse models of AD (Feng 
et al., 2006). Both, oxidative stress and deposition of ǃAPs, were found to be related with 
damage and severe modifications of brain lipids, proteins and DNA and to trigger apoptosis 
in AD brain (Feng et al., 2006). The authors summarize that these neuronal alterations in 
certain regions of AD brains are indicated by some pro-apoptotic markers such as increased 
levels of Par-4 (proapoptotic protein), elevated expression of Bax (apoptosis-effector gene) 
and upregulated caspases (enzymes, main executors of apoptosis). In this study the authors 
demonstrated that in transgenic mouse models of AD the early melatonin supplement 
prevents the abnormal upregulation of pro-apoptotic markers, thus inhibiting the 
consequential initiation of apoptotic cascade (Feng et al., 2006). However, melatonin fails in 
reducing ǃAPs-plaques and expressing antioxidant activity in old transgenic mouse models 
with already established AD (Quinn et al., 2005), thus limiting the therapeutic properties of 
exogenous melatonin only to the early stages of the disease. Nevertheless, the demonstrated 
neuroprotective effect of melatonin supplement in the early stage of AD (Feng et al., 2006) is 
promising for the prevention of AD development. Even though melatonin cannot inhibit the 
AD progression when it is in advanced stage, it shows to be useful in symptomatic 
treatment concerning sleep disturbance, sundowning etc. (Srinivasan et al., 2006).  
3.2.2 Parkinson’s disease (PD) and Huntington’s disease (HD)  
Several studies demonstrated the neuroprotective effect of melatonin in experimental models 
of PD. The protective effect is suggested to be complex due to the multiple targets involved 
in the melatonin action against oxidative stress, which is reviewed by Srinivasan (2002) and 
Srinivasan et al. (2005). However, some studies, summarized in the profound review of 
Srinivasan et al. (2006), reported about adverse effect of melatonin leading to aggravation of 
motor deficit in animal models of PD.  The presence of such contradictory results concerning 
melatonin action in PD models calls for more profound studies in this area.  
A large body of evidence supports the thesis that mitochondrial dysfunction and defects in 
brain energy metabolism trigger HD. Thus, the oxidative stress, excitotoxicity and apoptosis 
play crucial role in the pathogenesis of HD.  Therefore, the powerful anti-oxidant property 
of melatonin is proposed to have beneficial effect in HD patients. The experimental animal 
models of the disease use neurotoxins, quinolinic acid or 3-nitropropionic acid, to mimic 
mitochondrial dysfunction. When the effect of melatonin is tested in both models, the results 
showed prevention of oxidative stress damage and cell death in the quinolinic acid-model 
(Southgate et al., 1998) and protection of brain structures after induced oxidative stress in 3-
nitropropionic acid-models (Túnez et al., 2004). These results confirm the neuroprotective 
ability of melatonin against induced oxidative stress, but more experiments are needed to 
elucidate the melatonin effect on the other key factors of the disease - excitotoxicity and 
apoptosis.      
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Although various experimental models of AD, PD and HD prove the ability of exogenous 
melatonin to counteract diseases progression, the exact direct and indirect pleiotropic 
mechanisms of hormone actions are not completely revealed. Since central nervous system 
is highly susceptible to oxidative stress, it is suggested that the beneficial effect of melatonin 
is mostly due to its powerful antioxidant activity exerted at various levels. However, the 
research work in this area should be continued in order to elucidate the therapeutic 
potential of exogenous melatonin in neurodegenerative disorders. 
All these data suggest that melatonin is an important substance associated with numerous 
health benefits. Recent results proved that melatonin presented in plant foods preserves its 
bioavailability and suggest that it may counteract numerous disease conditions, including 
age-related and neurological disorders, carcinogenesis, cardiovascular diseases and diabetes 
(Iriti et al., 2010). It is noteworthy that grape and wine appear to be a rich source of 
melatonin and interestingly, it is found that melatonin level in grape could be increased by 
agrochemical treatments, while its level in wine may be modulated during the indoleamine 
synthesis by yeasts during the fermentation process of winemaking (Iriti et al., 2006). The 
presence of melatonin in these products gives new evidence for the healthpromoting effect 
of grape and wine.  
Grape and wine are rich in phytoceuticals but it is still little known about their beneficial 
effects on human health. Thus, metabolomics offers an opportunity for revealing the 
properties of a large number of plant secondary metabolites and for better understanding of 
their phytoceutical effects on humans. 
4. Conclusions 
So far, metabolite analyses of grape showed its rich content of secondary metabolites, which 
are highly beneficial for human health. This brief presenting of evidences about the 
beneficial effects of resveratrol and melatonin reveal only a little part of the effectiveness of 
grape secondary metabolites. The above reported data about very few grape secondary 
metabolites (resveratrol and melatonin) proved their biological potential as natural 
antioxidants, therapeutic agents for numerous pathological disorders and demonstrated the 
significance of grape and wine compounds. These natural substances showed an enormous 
promise for utilization as phytoceuticals for prevention and treatment of diseases (cancer, 
cardiovascular diseases, neurodegenerative disorders and others) which are so common for 
our society. However, it is still not completely clear which of the cellular mechanisms and 
signaling pathways are involved or activated by these phytoceuticals in the processes of 
disease prevention and therefore more detailed research in this area is necessary. 
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